TY - JOUR T1 -肺结核住院患者使用异烟肼、利福平和吡嗪酰胺的副作用危险因素JF -欧洲呼吸杂志JO - Eur Respir J SP - 2026 LP - 2030 VL - 9 IS - 10 AU - Schaberg, T AU - Rebhan, K AU - Lode，H Y1 - 1996/10/01 UR - //www.qdcxjkg.com/content/9/10/2026.abstract N2 -本研究的目的是确定在因肺结核住院的患者中，严重到足以引起异烟肼、利福平和吡嗪酰胺标准抗结核治疗不耐受的副作用的发生率。519例最初接受标准抗结核治疗的确诊肺结核患者在一所胸科教学医院的传染病科进行回顾性研究。测量了与治疗相关的严重副作用的发生率，导致三种标准药物之一的最终终止，并分析了不耐受的危险因素。519例患者中有121例(23%)因为严重的副作用需要最终终止异烟肼、利福平或吡嗪酰胺的治疗。导致一种药物最终终止的最严重的副作用是肝毒性(11%)、皮疹(6%)和关节痛(2%)。吡嗪酰胺的副作用(15%)比异烟肼(7%)和利福平(1.5%)更严重。多因素分析后，标准治疗不耐受的显著危险因素是有肝炎史(优势比(OR) 3.4;95%置信区间(95% CI) 1.6-7.6;P = 0.0026)和年龄> or = 60 yrs (OR 1.9; 95% CI 1.2-3.2; p = 0.017). Both of these risk factors were also significantly associated with the intolerance of pyrazinamide (history of hepatitis: OR 2.5; 95% CI 1.4-4.3; p = 0.0045; age > or = 60 yrs: OR 2.1, 95% CI 1.3-3.5; p = 0.0029) but not of isoniazid and rifampin. The side-effects of standard antituberculosis therapy are frequent in hospitalized patients aged > or = 60 yrs or with a history of previous hepatitis, and are probably due to pyrazinamide rather than to isoniazid or rifampin. ER -